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Introduction: The effect of ethnicity on the efficacy of salmeterol (S)+fluticasone
propionate (FP) has not been examined in Japanese and Caucasian asthmatics. In this
study, the efficacy of combination treatment with S and FP from a single inhaler (SFC) was
compared with concurrent treatment with S and FP administration from separate inhalers
(S+FP) in Japanese and Caucasian asthmatics.
Methods: This was a randomised, double-blind, crossover study in male and female
Japanese (n ¼ 18) and Caucasian (n ¼ 17) asthmatics (50–100% predicted FEV1; 435%
reversibility in sGaw). Subjects received SFC (S 50mcg/FP 250mcg b.i.d.) and S+FP
(S 50mcg b.i.d.+FP 250mcg b.i.d.) for 14 days. sGaw and FEV1 were determined 0–12 h
after the first and last doses.
Results: Treatment with both SFC and S+FP produced marked bronchodilation, which was
maintained 0–12 h after the first dose. Baseline sGaw and FEV1 increased up to 51% and
180mL, respectively, in Japanese subjects over 2 weeks of treatment, with similar
improvements in Caucasian subjects. On Day 14 the 0–12 h S+FP:SFC treatment ratios (90%
CI) for sGaw AUC and peak were 1.05 (0.98, 1.12) and 1.05 (0.97, 1.14), respectively, inPublished by Elsevier Ltd.
3422967; fax: +46 31 415249.
J. Lo¨tvall).
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Efficacy of salmeterol/fluticasone propionate in Japanese vs. Caucasian asthmatics 2489Japanese subjects, and 0.99 (0.92, 1.07) and 0.98 (0.89, 1.07), respectively, in Caucasian
subjects, with no difference between the two ethnic groups.
Conclusions: The finding of a similar significant bronchodilator response in Japanese and
Caucasian asthmatics following concurrent and combination treatment with salmeterol
and FP suggests that the therapeutic response to these agents is comparable and
independent of ethnicity in Japanese and Caucasian asthma patients.
& 2007 Published by Elsevier Ltd.Introduction
Combination therapy of an inhaled corticosteroid (ICS) and a
long-acting beta2-agonist (LABA) directly targets the under-
lying components of airway inflammation and smooth
muscle dysfunction and is recommended for treatment of
persistent asthma.1 The combination of the LABA salmeterol
(S) and the ICS fluticasone propionate (FP) (SFC; SeretideTM/
AdvairTM/VianiTM/AdoairTM) has been shown to have super-
ior efficacy to either component given separately,2 a higher
dose of ICS alone,3–6 or a combination of ICS and a
leukotriene antagonist7,8 or theophylline.9 SFC is available
in many countries worldwide with an estimated cumulative
exposure of more than 30 million patient years.
International community surveys indicate that the control
of asthma currently achieved in Japan and the West falls
short of asthma management goals.10,11 The definition and
grading of asthma are closely aligned between Japan12 and
the rest of the world.1 However, despite a trend for asthma
in Japan to be less severe than global averages,11 this is
associated with significantly more chronic symptoms,
unscheduled emergency room or hospital visits and a higher
mortality rate,10 suggesting a poor degree of asthma
control.
The recommendations for asthma pharmacotherapy and
definitions of asthma control are comparable in Japan12 and
in the rest of the world.1 Although both S and FP are
available in Japan at similar doses to the rest of the world,
the SFC has only recently become available. Furthermore,
studies comparing the SFC with its components have largely
been performed in Caucasian subjects and there is no similar
information in Japanese asthmatics. The present study was
performed to determine the efficacy of the SFC delivered
from a single DiskusTM dry powder inhaler in comparison
with concurrent administration of S and FP from separate
DiskusTM inhalers in Japanese asthmatics. Specific airways
conductance (sGaw), as measured by whole-body plethys-
mography, was selected as a sensitive measure of airway
tone and bronchodilation. A comparator group of matching
Caucasian asthmatics was also included as the effects of the
SFC on lung function, as determined by sGaw, has not been
previously evaluated in any ethnic group.Methods
This was a double-blind, repeat dose two-way, crossover
study conducted at two centres in Japan and Sweden. The
protocol was approved by the independent institutional
review boards at these centres. All patients provided
written informed consent and agreed to follow studyprocedures, and the study was conducted in accordance
with good clinical practice guidelines and all applicable
regulatory requirements, including the Declaration of
Helsinki (South Africa, 1996).
Study population
Male and female Japanese and Caucasian asthmatic subjects
(18–70 years) were recruited into the study. Ethnic origin
was defined by either having four ethnic Japanese grand-
parents and being able to speak Japanese or by having four
grandparents who were descendants of European Cauca-
sians. Current smokers or ex-smokers with a heavy smoking
history were excluded in order to eliminate the potential
effects of current smoking on lung function and to select
patients who were less likely to have COPD. Ex-smokers
were included if they had a pack history of o20 years
[number of pack years ¼ (number of cigarettes per day/20)
number of years smoked]. Subjects were included only if
they had a documented history (46 months) of mild or
moderate asthma diagnosed according to current guidelines1
and an forced expiratory volume in 1 s (FEV1) of 50–100% of
predicted.13 The presence of reversible airways disease was
confirmed at screening by an increase in sGaw of at least
35% above baseline within 30min of administration of
200mcg salbutamol. All subjects received ICS for at least 6
weeks prior to participation in the study with no significant
change in medication within 4 weeks of the study start.
Injectable or oral corticosteroids were not taken within 12
weeks and LABAs within 1 week of screening. All other
asthma medications other than the study medication were
discontinued from the start of the run-in period and
throughout the study. Exclusion criteria included lower
respiratory tract infection within 4 weeks of the study start,
a history of claustrophobia, an acute asthma exacerbation
requiring emergency room treatment (within 4 weeks of the
study) or hospitalisation (within 12 weeks) and female
subjects who were pregnant or lactating.
Study design
Subjects attended an initial screening visit and were then
trained in the whole-body plethysmograph technique. Their
competence was assessed by the ability to perform three
screening measurements within 15% of each other. Subjects
were also trained in the technique for measurement of peak
expiratory flow (PEFR) and in using the DiskusTM dry powder
inhaler. Reversibility testing was performed either at this
screening visit or at a second visit at least 1 week later to
allow for washout of asthma medications. Subjects were
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Table 1 Subject demographic details.
Characteristic Japanese
(n ¼ 18)
Caucasian
(n ¼ 17)
Gender (m/f) 9/9 7/10
Age (years) 41.6 (14.7) 44.8 (14.9)
Height (cm) 163.3 (8.1) 168.5 (8.7)
Weight (kg) 60.9 (12.4) 72.8 (16.7)
BMI (kg/m2) 22.6 (3.0) 25.6 (5.4)
FEV1
 (% predicted) 81 (51, 98) 91 (52, 100)
sGaw reversibility
(%)
72 (38, 181) 88 (42, 359)
FEV1 reversibility

(%)
10 (6, 24) 14 (5, 55)
Data are mean (SD).
Median and range.
M. Kawai et al.2490then randomised to one of two treatment groups. Each
subject received either concurrent salmeterol (50mcg)
b.i.d. and FP (250mcg) b.i.d. (S+FP) or their combination
(SFC) b.i.d. and placebo (lactose) b.i.d. from two separate
inhalers for a 14-day treatment period. Each subject then
received the alternative treatment during a second 14-day
treatment period. All treatments were taken as single
inhalations from matching separate DiskusTM dry powder
inhalers. During the 14–21-day run-in (pre-treatment period
1), 14–21-day washout (between treatment periods) and
7–21-day run-out (post-treatment period 2 to follow-up)
periods all subjects received 200mcg b.i.d. beclomethasone
dipropionate (BDP). Salbutamol prn was allowed as rescue
medication throughout the study.
Subjects attended the clinic for measurement of pulmon-
ary function on the first (Day 1) and last (Day 14) day of each
treatment period. They refrained from consumption of
alcohol and strenuous exercise for 24 h and from caffeine-
containing foods or drink for 8 h before and throughout each
study day. A light breakfast was consumed at least 1 h before
dosing on study days and food consumption was similar on
each study day.
Measurements
Lung function was measured using identical Jaeger Master-
ScreenTM, (Viasys Healthcare GmbH, Germany) whole-body
plethysmographs at both study sites. On Days 1 and 14 of
each treatment period, specific airways conductance (sGaw)
was measured pre-dose and 1, 2, 3, 4, 6, 8 and 12 h post-
dose. At each time point three sGaw measurements were
taken and recorded. Following sGaw measurements, FEV1
was recorded at the same time points as the best of two
technically correct procedures. PEFR was also recorded by
the subjects throughout the study using a Mini-Wright peak
flow meter and was recorded as the best of three
measurements taken immediately prior to taking study
medication during the treatment periods or BDP during the
run-in, washout and run-out periods.
The primary endpoints for the study were the Day 14
sGaw area under the 0–12 h time–response curve (AUC0–12)
as well as the peak (0–12 h) response. Secondary endpoints
were the same sGaw parameters on Day 1, as well as the Day
1 and Day 14 FEV1 (AUC0–12 and peak (0–12 h)), and baseline
pre-treatment (trough) sGaw and FEV1.
Statistics
Power calculations were based on a conservative estimate of
intra-subject variability in sGaw using a standard deviation
(log scale) of 0.3 (based on previous data from studies
performed in Caucasian populations in the Swedish centre).
A total of 16 subjects were required to provide at least 90%
power to declare equivalence based sGaw in either popula-
tion. Equivalence would be declared if the 90% confidence
interval (CI) for the ratio of both endpoints for the two
treatments fell between 0.7 and 1.43. Treatment effect
ratios were based on analysis of the sGaw area under the
curve (AUC) from 0 to 12 h after inhalation.
The primary statistical analysis examined the effects of
S+FP and SFC treatments on sGaw in Japanese subjects onDay 14. Similar secondary analyses were conducted to
examine the effects in both the Japanese and Caucasian
sub-populations on Day 1, Day 14 and the change between
Days 1 and 14 in both sGaw and FEV1.
All data were analysed using ANCOVA (baseline response,
period, day, population and treatment as fixed effect;
subject as random effect) in SAS v8 PROC MIXED. The three-
dimensional interaction was fitted to extract treatment
differences within populations, on each treatment day.
Separate models were fitted for FEV1 and sGaw. The
relationships between height and FEV1 and height and sGaw
were plotted by graphical means only. The sGaw parameters
were log-transformed prior to all analyses. Data are
presented as mean for FEV1 and PEF and as geometric
means for sGaw, in some instances together with the 95%
confidence intervals.Results
A total of 18 Japanese and 17 Caucasian asthma patients
were randomised into the study. All patients completed the
study with no withdrawals. The Japanese subjects were, on
average, slightly younger, shorter and lighter with a lower
BMI than the Caucasian subjects (Table 1). At screening, all
the Caucasian subjects and 15 out of 18 of the Japanese
subjects had a history of asthma for at least 5 years (the
remaining three had a 1–5-year history of asthma). The
distribution of predicted FEV1 (%) was similar in both the
Japanese and Caucasian subjects, although the absolute
individual FEV1 values tended to be slightly lower in
the Japanese group compared with the Caucasian group
(Table 1).sGaw
On the first day of dosing, both S+FP and SFC produced an
increase in sGaw in both Japanese and Caucasian subjects
(Figure 1). The maximal response was seen at approximately
1–2 h after dosing and was followed by a gradual decline
which did not return to baseline by the end of the 0–12 h
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Figure 1 Absolute mean sGaw recorded in Japanese and
Caucasian asthmatic subjects 0–12 h post-dosing with concur-
rent salmeterol (S) 50mcg b.i.d. and fluticasone propionate (FP)
250mcg b.i.d. delivered from separate inhalers (S+FP) and their
combination (SFC) delivered from a single inhaler on Day 1 (A)
and Day 14 (B).
Table 2 Improvement in pre-treatment (trough) sGaw and FEV1
propionate (FP) 250mcg b.i.d. delivered from separate inhalers
inhaler in Japanese and Caucasian asthmatic subjects.
Parameter Groups Geome
Day 14
sGaw (1/kPa s) Japanese
S+FP 1.17
SFC 1.07
Caucasian
S+FP 1.12
SFC 1.13
Day 14
FEV1 (L) Japanese
S+FP 2.50
SFC 2.62
Caucasian
S+FP 3.04
SFC 3.01On Day 14 S+FP and SFC increased sGaw to a similar
extent in both Japanese and Caucasian subjects (Figure 1).
The absolute sGaw values were similar to those on Day 1,
with a similar response in both populations. The Day 14
0–12 h S+FP:SFC treatment ratios (90% CI) for sGaw AUC and
peak were 1.05 (0.98, 1.12) and 1.05 (0.97, 1.14),
respectively, in Japanese subjects, and 0.99 (0.92, 1.07)
and 0.98 (0.89, 1.07), respectively, in Caucasian subjects,
with no difference between the two ethnic groups. Repeat
dose administration of both S+FP and SFC treatments also
increased baseline (trough) pre-treatment sGaw by 34–41%
and by 31–51% in Caucasian and Japanese subjects,
respectively (Figure 1; Table 2).FEV1
The FEV1 response to S+FP and SFC was similar to that seen
for sGaw. The extent of bronchodilation was comparable for
both treatments and between Japanese and Caucasian
subjects (Table 2). S+FP and SFC resulted in an increase in
mean pre-treatment (trough) FEV1 of 170–180mL and
200–270mL in Japanese and Caucasian subjects, respec-
tively (Figure 2; Table 2).Relationship between sGaw and FEV1 and height
The relationship between sGaw and FEV1 and height in
Japanese and Caucasian is shown in Figure 3. The data
presented represents the maximal value obtained in each
individual subject following S+FP and SFC treatments, and
therefore represent the optimal bronchodilator response
achieved by each individual during the study. In both
Japanese and Caucasian patients there was a linear
relationship between FEV1 and height that appeared to be
similar in the two ethnic groups. In contrast, there was nowith concurrent salmeterol (S) 50mcg b.i.d. and fluticasone
(S+FP) and their combination (SFC) delivered from a single
tric mean
Day 1 Ratio (95% CI)
0.77 1.51 (1.34, 1.70)
0.82 1.31 (1.16, 1.47)
0.84 1.34 (1.18, 1.52)
0.80 1.41 (1.25, 1.60)
Day 1 Difference (L) (95% CI)
2.33 0.18 (0.07, 0.28)
2.44 0.17 (0.06, 0.28)
2.77 0.27 (0.16, 0.38)
2.81 0.20 (0.09, 0.32)
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Figure 2 Mean FEV1 (difference from baseline) recorded in
Japanese and Caucasian asthmatic subjects 0–12 h post-dosing
with concurrent salmeterol (S) 50mcg b.i.d. and fluticasone
propionate (FP) 250mcg b.i.d. delivered from separate inhalers
(S+FP) and their combination (SFC) delivered from a single
inhaler on Day 1 (A) and Day 14 (B).
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Figure 3 Relationship between (A) height and maximal FEV1
and (B) height and maximal sGaw in individual Japanese and
Caucasian asthmatic subjects. FEV1 and sGaw values represent
the highest value achieved by each individual during the study,
irrespective of treatment.
M. Kawai et al.2492relationship between sGaw and height, presumably reflect-
ing the factor that sGaw is independent of lung volume.
PEFR
There was an increase in pre-treatment PEFR on switching
from BDP to SFC, with a maximal effect achieved within 2–3
days. At the end of the treatment period there was
progressive decline in PEFR on switching back to BDP alone,
with PEFR reaching the lowest values similar to those
seen during the run-in period after approximately 1 week
(Figure 4). The PEFR response and washout of this response
was similar whether S and FP were delivered concurrently
from separate inhalers or as a combination from a single
inhaler.
Safety and tolerability
Both treatment regimens were well tolerated and demon-
strated comparable adverse events profiles, with few
adverse events reported in either Japanese or Caucasian
subjects. There were no subject withdrawals.
Discussion
This is the first study to demonstrate that the bronchodilator
response, as determined by measurement of specific airwaysconductance, to a combination of S and FP from a single
inhaler is comparable to concurrent treatment with S and FP
from separate inhalers in Japanese asthmatic subjects. The
bronchodilator response was maintained under repeat dose
conditions and was similar to that seen in a matched group
of Caucasian asthmatic subjects. Consequently, a significant
ethnic difference between Japanese and Caucasian asth-
matics in the therapeutic response to salmeterol and FP is
considered to be unlikely.
The primary endpoint for this study was 0–12 h specific
airways conductance (sGaw; AUC and peak response) in
Japanese asthmatic subjects after 14 days dosing. The
results clearly show that using this measure, SFC treatment
was equivalent to S+FP treatment as the 90% CIs for the
comparisons between treatments for both AUC and peak
sGaw included unity and were considerably within the limits
set a priori for equivalence. Similar equivalence was also
seen between the treatments on Day 1 in Japanese
asthmatic subjects as well as on Day 1 and Day 14 in
Caucasian asthma subjects. These results are in agreement
with large clinical studies that demonstrated the equiva-
lence of concurrent and combination treatments predomi-
nantly in Caucasian asthmatics.14 However, utilising sGaw
and a crossover design in the present study enabled the
demonstration of equivalence in Japanese subjects with
ARTICLE IN PRESS
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Figure 4 Mean morning pre-treatment peak expiratory flow
rate (PEFR) recorded during the run-in period, treatment period
1 and washout period in Japanese (n ¼ 9) and Caucasian (n ¼ 8)
asthmatic subjects. Data represent subjects who received
salmeterol (S) 50mcg+fluticasone propionate (FP) 250mcg b.i.d.
delivered as a combination (SFC) from a single inhaler during
treatment period 1.
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manoeuvres such as PEFR.14
The initial bronchodilation with salmeterol and FP seen on
Day 1 of dosing was comparable for both concurrent and
combination treatments in Japanese and Caucasian sub-
jects. This response was similar to that seen previously in
large-scale trials2,15 and is largely attributable to the
salmeterol component.2 Secondary measures of lung func-
tion also showed improvement in both populations including
pre-treatment (trough) PEF which progressively increased
on repeat dosing with S and FP despite previous main-
tenance treatment with BDP. This progressive improvement
in underlying lung function is attributed to the FP
component.2 The beneficial effect of S and FP on lung
function was also demonstrated during the washout period
when cessation of treatment and switching to BDP alone
resulted in a slow progressive decline in lung function (PEF)
which did not reach a nadir until approximately 5 days. The
relative contributions of S and FP to this prolonged duration
of action following treatment cessation could not be
discriminated in the present study.
There were no significant differences between Japanese
and Caucasian asthmatic subjects in the initial response,
progressive improvement on repeat dosing or rate of decline
in lung function on cessation of dosing with S and FP (either
concurrent or combination). These results suggest that
significant ethnic differences between Japanese and Cau-
casian asthmatics in the response to S and FP combination
are unlikely, and that efficacy similar to that seen in
Caucasian asthmatics may be anticipated in Japanese
asthmatics.
In this study, sGaw was selected as a sensitive, effort-
independent measure of airway conductance. In comparison
with forced manoeuvres such as FEV1, sGaw is a more
sensitive indicator of lung function and bronchodilator
response, irrespective of drug class, producing changes that
are typically 3–4-fold greater than in changes FEV1. Since
the magnitude of variability for the two measures is
similar,16 the power to detect a given change is much higher
for sGaw than FEV1. Consequently, by using sGaw it ispossible to evaluate bronchodilator responses in fewer
subjects than with FEV1.
In clinical studies, sGaw has been shown to be sensitive
and discriminative in detecting bronchodilator responses in
patients with asthma and COPD16,17 as well as in paediatric
asthmatics18 and even in non-asthmatic healthy sub-
jects.19,20
Cross-study comparisons of drug responses between
different ethnic groups are often complicated by differences
in inclusion criteria, methodology, data collection and
analysis. In order to overcome some of these problems the
present single protocol study included a comparator group
of matching Caucasian subjects, use of identical plethysmo-
graphy equipment at both the Japanese and Caucasian study
sites and joint staff training sessions. These procedures are
likely to have directly contributed to the good reproduci-
bility and low variability in the bronchodilator response seen
in both the Japanese and Caucasian subjects and facilitated
the demonstration of equivalence between concurrent and
combination treatments.
Although demographic differences can complicate com-
parisons of clinical results between ethnic groups, differ-
ences in lung function still exist even after detailed
adjustment for frame size.21,22 In this study, Japanese and
Caucasian asthmatic subjects were well matched for gender,
age, asthma history and range of predicted FEV1 although
the Japanese subjects tended to be smaller. Absolute
individual FEV1 values were slightly lower in the Japanese
subjects at screening, pre- and post-treatment although
there was considerable overlap between the groups. Despite
the limited number of subjects in the study, the linear
relationship between height and FEV1 was similar for both
Japanese and Caucasian subjects, suggesting that frame size
alone rather than ethnicity could account for the FEV1
differences. In contrast, there was no obvious relationship
between size and sGaw in either population presumably
reflecting the fact that this parameter is normalised for
total gas volume and is independent of lung volume.23
Concurrent and combination treatments were well
tolerated in Japanese asthmatics with few adverse events
reported and an incidence comparable with the Caucasian
asthmatic subjects. In Japanese asthmatics, systemic
exposure to salmeterol and FP following repeat dosing with
SFC is comparable to that noted in Caucasian subjects (data
on file) and significant ethnic differences in tolerability are
therefore not anticipated.
In conclusion, the results of this study indicate a similar
lung response, as determined by sGaw, to repeat dose S and
FP (either co-administered or in combination) in Japanese
and Caucasian asthmatic subjects. There were no significant
ethnic differences in therapeutic response while minor
differences in baseline asthma demography could be
attributed to differences in frame size. These results
suggest that the therapeutic response to SFC would be
comparable in Japanese and Caucasian asthmatic patients.Acknowledgements
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